Your search returned 10 results. Subscribe to this search

|
1. Myeloid sarcoma with megakaryoblastic differentiation presenting as a breast mass

by Obiorah, Ifeyinwa E.

Published: 2018Citation: Hematology/oncology & stem cell therapy. 11(3):178-182, 2018 Sep..Institution: MedStar Washington Hospital Center.Department: Pathology.Publication: Journal Article.Article type: Journal Article.Full author list: Obiorah IE; Ozdemirli M.UI/PMID: 29684340.Digital Object Identifier: https://dx.doi.org/10.1016/j.hemonc.2018.03.001 (Click here)
2. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial

by Swain, Sandra M.

Published: 2017Citation: JAMA Oncology. 3(3):335-341, 2017 Mar 01.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Gavin PG; Song N; Kim SR; Lipchik C; Johnson NL; Bandos H; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE Jr; Jeong JH; Costantino JP; Wolmark N; Paik S; Pogue-Geile KL.UI/PMID: 27812689.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.4884 (Click here)
3. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

by Swain, Sandra M.

Published: 2017Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Smith JW 2nd; Buyse ME; Rastogi P; Geyer CE Jr; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N.UI/PMID: 27693116.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clbc.2016.07.008 (Click here)
4. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl

by Swain, Sandra M.

Published: 2016Citation: Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S.UI/PMID: 26759246.
5. Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

by Swain, Sandra M.

Published: 2016Citation: Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Cecchini RS; Swain SM; Costantino JP; Rastogi P; Jeong JH; Anderson SJ; Tang G; Geyer CE Jr; Lembersky BC; Romond EH; Paterson AH; Wolmark N.UI/PMID: 26545405.Digital Object Identifier: http://dx.doi.org/10.1158/1055-9965.EPI-15-0334-T (Click here)
6. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

by Swain, Sandra M.

Citation: Cancer. 120(17):2657-64, 2014 Sep 1..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't.Full author list: Kaufman PA; Bloom KJ; Burris H; Gralow JR; Mayer M; Pegram M; Rugo HS; Swain SM; Yardley DA; Chau M; Lalla D; Yoo B; Brammer MG; Vogel CL.UI/PMID: 24930388.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1002/cncr.28710 (Click here)
7. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

by Swain, Sandra M.

Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM.UI/PMID: 24129974.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1007/s10549-013-2710-z (Click here)
8. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

by Swain, Sandra M.

Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J.UI/PMID: 23969513.Digital Object Identifier: http://dx.doi.org/10.1097/CAD.0000000000000016 (Click here)
9. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

by Swain, Sandra M.

Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 24262440.Digital Object Identifier: http://dx.doi.org/10.1093/jnci/djt321 (Click here)
10. Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer

by Swain, Sandra M.

Citation: Clinical Breast Cancer. 12(4):232-9, 2012 Aug..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S..Full author list: Levine PH; Portera CC; Hoffman HJ; Yang SX; Takikita M; Duong QN; Hewitt SM; Swain SM.UI/PMID: 22694825.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/j.clbc.2012.04.005 (Click here)

Powered by Koha